Analysis of 10 ovarian cancer cell lines: 4 ovarian serous adenocarcinomas, 1 paclitaxel/cisplatin resistant ovarian adenocarcinoma cell line derivative, 5 ovarian clear cell adenocarcinomas. Expression profile of each cell line compared to its sensitivity to paclitaxel and cisplatin.
Komatsu M, Hiyama K, Tanimoto K, Yunokawa M et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther 2006 Mar;5(3):767-75. PMID: 16546992